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ABSTRACT
Diagnosing symptoms of psychological distress can be challenging in migrants living with HIV
(MLWH) living in Western Europe. We evaluated the Hospital Anxiety and Depression Scale
(HADS) as a screening tool for psychological distress. Additionally, the association between
psychological distress and adherence to combination Antiretroviral Therapy (cART) was
determined. Socio-demographic and clinical characteristics, psychosocial variables, and self-
reported adherence to cART data were collected. 306/352 participants completed the HADS.
A HADS+ (≥15, at risk for psychological distress) was found in 106/306. The Composite
International Diagnostic Interview (CIDI) was completed by 60/106. The HADS was repeated in 58
participants as the time between the ﬁrst HADS and the CIDI was more than three months. In
21/37 participants with a HADS+ (57%) within three months before the CIDI a diagnosis of
depression or anxiety disorder based on the CIDI was found. Participants with a HADS+ were
more likely to be non-adherent (71.3% vs. 43.6%). In a large group of MLWH in the Netherlands,
35% were at risk for symptoms of psychological distress. The HADS seems to be a suitable
screening tool for MLWH.
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Introduction
Since the introduction of antiretroviral therapy (ART),
life expectancy of people living with HIV (PLWH) has
greatly improved (May et al., 2014; Trickey et al. 2017).
Subsequently, the focus of care for PLWH is not merely
on their quantity of life years to gain, but more and more
on their quality of life.
Mental health is an important issue. Symptoms of
anxiety and depression are common among PLWH. In
fact, 33% of a large sample of PLWH in Canada and
Western Europe were screened positive for symptoms
of anxiety (Robertson et al., 2014). Additionally, a recent
meta-analysis showed prevalence’s of depressive symp-
toms in 12.8–78% of PLWH living in low, middle and
high-income countries (Uthman, Magidson, Safren, &
Nachega, 2014). Presence of symptoms of anxiety or
depression (“psychological distress”) has been linked
with decreased adherence to ART, poor HIV treatment
outcomes, and mortality (Brandt et al., 2017; Campos,
Guimaraes, & Remien, 2010; Gonzalez, Batchelder,
Psaros, & Safren, 2011; Langebeek et al., 2014; Shacham,
Nurutdinova, Satyanarayana, Stamm, & Overton, 2009;
Todd et al., 2017; Uthman et al., 2014). PLWH with
anxiety symptoms can have diﬃculty engaging in beha-
viors that are health promoting (Shacham et al., 2009).
Depressive symptoms, such as loss of interest, dimin-
ished concentration, feelings of worthlessness, and recur-
rent thoughts of death can negatively inﬂuence the self-
management activities required by HIV treatment (Gon-
zalez et al., 2011).
In the Netherlands, 41% of the people living with HIV
are immigrants and most frequently originate from Sub
Saharan Africa (36%) and Latin America (18%)(Van
Sighem et al., 2013). This is a group of special attention
as they, being immigrants and living with HIV, might
be even more at risk of symptoms of anxiety and
depression. In fact, previous studies have reported that
immigrants (regardless of their HIV status) in Europe
are more prone to certain psychiatric disorders due to
the process of migration (Bhugra et al., 2014). This is
also shown at a more local level in the Netherlands as
immigrants have shown a higher prevalence of depressive
and anxiety disorders compared to the native Dutch
population (de Wit et al., 2008). Among immigrant
people living with HIV (MLWH) from outside of Wes-
tern Europe, poorer treatment adherence, more
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virological failure, and poorer psychosocial outcomes
compared to PLWH born in Western Europe have been
found (Feuillet et al., 2017; Monge et al., 2013; Nellen
et al., 2009; Staehelin et al., 2012; Sumari-de Boer, Spran-
gers, Prins, & Nieuwkerk, 2012). For example, one study
reported symptoms of depression in 38% of the MLWH
compared to 12% in Dutch PLWH (Sumari-de Boer
et al., 2012). In this study, depressive symptoms were
associated with viral load but not with adherence. How-
ever, to our knowledge no other studies have reported
on the association between psychological distress and
adherence to HIV-treatment in MLWH in Europe.
The Hospital Anxiety and Depression Scale (HADS)
is a screening tool that has been developed to measure
symptoms of anxiety and depression in a general medical
population in 1983 (Zigmond & Snaith, 1983). It con-
tains 14-items that focus on anxiety and depression.
This tool can be self-administered and during the last
decades it has been translated into multiple languages
and validated within diﬀerent populations around the
world (Bjelland, Dahl, Haug, & Neckelmann, 2002; Herr-
mann, 1997). Diagnosing anxiety or depressive disorders
or symptoms in a uniform matter can be challenging in
MLWH living in Western Europe due to language and
cultural barriers. The HADS might be a rapid screening
tool that HIV care providers can administer during their
consultations, or that can be self-administered. However,
whether the HADS can be used among non-Western
MLWH living in Western Europe has yet to be
determined.
The primary objective of this study was to evaluate
whether the HADS can be used in standard care of
MLWH to measure psychological distress. The HADS
was compared with the Composite Diagnostic Interview
(CIDI) which was used as a “gold standard” (WHO,
2017). Since the association between depressive disorders
and treatment adherence in MLWH has not been exten-
sively studied, the association between psychological dis-
tress and treatment adherence to combination
antiretroviral therapy (cART) was determined.
Materials and methods
Study population
Between November 2012 and July 2013, a total of 352
patients from the outpatient clinics of the two Rotterdam
HIV treatment centers (Erasmus University Medical
Center andMaasstadHospital) were included in the ROt-
terdam ADherence (ROAD) Project. This study was set
up to investigate risk factors for non-adherence to HIV
treatment in MLWH (Been et al., 2016). Eligible partici-
pants had to be ﬁrst or second generation immigrants,
aged 18 years or older, diagnosed with HIV, and had to
be suﬃciently ﬂuent in one of the following languages:
Dutch, English, French, Spanish, or Portuguese.
The study was approved by the Medical Ethics Com-
mittee of the Erasmus University Medical Center. Writ-
ten informed consent was provided by all participants
prior to participation.
Data collection
Sociodemographic and psychosocial data was collected
through both the medical chart and an interviewer admi-
nistered questionnaire (Been et al., 2016). Characteristics
of all participants in the ROAD-project have been pre-
sented previously (Been et al., 2016). In short, the
eight-itemMedical Outcomes Study Socials Support Sur-
vey (mMOS-SS) was used to assess experienced social
support (Moser, Stuck, Silliman, Ganz, & Clough-Gorr,
2012). To assess the amount of internalized HIV-related
stigma experienced, the six-item Internalized AIDS-
Related Stigma Scale was used (Kalichman et al., 2009).
HIV-treatment adherence self-eﬃcacy was assessed
through the 12-item HIV Treatment Adherence Self-
Eﬃcacy Scale (HIV-ASES) (Johnson et al., 2007). The
12-item Short Form Health Survey (SF-12) was used to
determine physical and mental quality of life (Ware Jr.,
Kosinski, & Keller, 1996). Self-reported adherence to
cART was measured through a four-item measure devel-
oped from adherence questions used in previous studies
(Been et al., 2016). Data on HIV-RNA, CD4 cell count,
and cART use were collected from the ATHENA
national observational HIV cohort database (the Dutch
national HIV registry of HIV treatment centers). When
incomplete, data were cross-checked with medical
records.
Symptoms of anxiety or depression were measured
using the Hospital Anxiety and Depression Scale (Zig-
mond & Snaith, 1983). In this 14-item questionnaire
focusing on feelings in the past seven days, seven items
focus on anxiety (HADS-A; e.g., “I get a sort of frigh-
tened feeling as if something awful is about to happen”)
and seven items on depression (HADS-D; e.g., “I feel
cheerful”). It can be self-administered and it takes
about ﬁve minutes to complete the questionnaire
(Stern, 2014). Each item can be answered on a four-
point Likert scale and therefore the possible score
range for each subscale is 0–21. Both scores can be com-
bined to produce one scale that can be used to screen for
general psychological distress, the total HADS score. As
the total HADS score, rather than the score on the
depression subscale, was shown to have the highest posi-
tive predicting value in detecting an psychiatric disorder
in a previous study, we choose to focus on the total
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HADS score (Spinhoven et al., 1997). A higher score
indicates higher levels of psychological distress and
a HADS score ≥15 indicates psychological distress
(Ibbotson, Maguire, Selby, Priestman, & Wallace, 1994;
Kugaya et al., 2000; Roth et al., 1998). The HADS was
oﬀered to all 352 HIV+ migrants in Dutch, English,
French, and Spanish. Similar to the general question-
naire, the HADS was interviewer administered. Due to
logistical challenges, in 51 participants the HADS was
completed >100 days after the general questionnaire.
Participants with a HADS score ≥15 (HADS+) were
invited for an appointment to take the Composite Inter-
national Diagnostic Interview (CIDI). The CIDI is a struc-
tured interview designed to be used by trained lay
interviewers for the assessment of mental disorders
according to the deﬁnitions and criteria of ICD-10 and
DSM-IV (Booth, Kirchner, Hamilton, Harrell, & Smith,
1998; Michigan, 2017; Robins et al., 1988; WHO, 2017).
It has been used as a “gold standard” in previous studies.
The CIDI lifetime version 2.1 was used to conﬁrm the
indication of psychological distress as a result from the
screening with the HADS (Penninx et al., 2008). This ver-
sion focusses on Dysthymia, Major Depressive Disorder,
General Anxiety Disorder, Panic Disorder, Social Phobia,
and Agoraphobia. The CIDI could only be administered
in Dutch or English. We aimed to administer the CIDI
within three months after the HADS was completed.
This was not possible in almost all participants and there-
fore the HADS was completed again just before the CIDI
was administered. Regardless of the results from the
second HADS the CIDI was administered in all partici-
pants with an initial HADS+. The interviewers who admi-
nistered the CIDI had received a formal training (GGZ
inGeest, VUUniversityMedical Center).When the results
from the CIDI were indicative for depression or anxiety
disorder, participants were oﬀered a consultation with a
psychiatrist (care as usual) and their treating HIV phys-
ician was informed.
Statistical analyses
Reliability analysis of the HADS was performed by
measuring the internal consistency using Cronbach’s α
for both the subscales of the HADS and the total scale.
Categorical data between groups was compared using
Chi2 and Fisher-Freeman-Halton-Exact tests. To com-
pare continuous data, T-tests and the Mann–Whitney
tests were used when appropriate. Patients were
deﬁned as cART experienced when they used cART >6
months prior to inclusion. An undetectable viral load
was deﬁned as HIV1-RNA or HIV-2 RNA <50 copies/
ml. Participants who had missing data on the HADS
were excluded.
The association between the HADS and CIDI was
determined using the Chi2 test.
Results
Patients’ characteristics
The HADS was completed by 306 patients: 240 in Dutch,
49 in English, 10 in French, and 7 in Spanish (Figure 1).
Mean age of all participants was 41.7 years (sd, 10.5) and
the majority were men (57%). Most originated from Sub
Saharan Africa (38.2%), followed by Latin America
(23.5%), the Caribbean (19.9%), and then regions cate-
gorized as “other” (18.3%) (Table 1). These patients
were not statistically signiﬁcantly diﬀerent in baseline
characteristics when compared to the 46 patients that
did not complete the HADS (data not shown). Reasons
for not completing the HADS were mainly: having a
language barrier, lack of time after completing the gen-
eral questionnaire, and refusal. A total of 106/306 of
the participants (34.6%) had a HADS+ (score of ≥15)
(Table 1).
In 51 participants, the HADS was completed >100
days after the general questionnaire. When comparing
this group with the participants that completed the
HADS <100 days after the general questionnaire, they
were older (45 years vs. 41 years, p <0.01), and more fre-
quently received cART > 6 months prior to inclusion
(98% vs. 83.1%, p < 0.05).
In terms of demographic characteristics, participants
with a HADS+ were less likely to have paid employment
(29.2% vs. 51%, P < 0.001) (Table 1).
Participants with a HADS+ had a lower median social
support score (62.5 vs. 79.7, P < 0.001), higher median
internalized HIV-related stigma score (17 vs. 14, P <
0.001), lower median treatment adherence self-eﬃcacy
score (99 vs. 109, P < 0.001), lower median physical qual-
ity of life score (46.0 vs. 53.8, P0.001), and a lower
median mental quality of life score (35.9 vs. 53.6, P <
0.001) (Table 1).
A total of 259 patients who completed the HADS were
deﬁned as cART experienced. Detectable HIV-RNA was
found in 12.6% of the participants with a HADS+ com-
pared to 9.3% in the HADS− group. (P0.41). Participants
with a HADS+ were more likely to be self-reported non-
adherent to cART (71.3% vs. 43.6%, Table 1) (OR = 3.17;
95%CI: 1.82–5.52).
Internal consistency
The HADS Cronbach’s α for anxiety was 0.79,
for depression 0.76, and for the total HADS 0.87
(Table 2).
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CIDI in MLWH
The CIDI was administered to 67/106 (63%) participants
with a HADS+ (Figure 1). However, in six participants
the time between the HADS and the CIDI was more
than three months while the HADS was not repeated.
These participants were excluded from analyses. Of the
remaining 61 participants, the HADS was repeated in
58. All participants had a HADS+ during the ﬁrst assess-
ment and 24/61 (39%) were found to have a HADS− in
the second HADS. Diﬀerences in HADS scores ranged
from 1 to 21.
In all 61 patients with either HADS+ or HADS−more
than 3 months after the initial HADS+ (second assess-
ment), the CIDI was performed (Table 3). The CIDI
was partially or fully completed by 60/61. Of the partici-
pants with a HADS+, 21/37 (57%) had a diagnosis of
depression or anxiety disorder based on the CIDI and
4/23 (17%) of the participants with a HADS− were diag-
nosed with a depressive or anxiety disorder based on the
CIDI as well (P < 0.01).
Discussion
In this study, we assessed whether the Hospital Anxiety
and Depression Scale (HADS) can be used in standard
of care of MLWH to measure psychological distress.
The results demonstrated that the HADS can be easily
administered in MLWH from diﬀerent origins. In
Figure 1. Flow diagram of patient inclusion and completion of questionnaires.
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addition, we assessed the association between psycho-
logical distress and treatment adherence to cART. This
association was found, indicating that the HADS may
be a valuable addition in clinical care for MLWH.
When symptoms of psychological distress have been
determined, HIV care providers need to be aware
about the risk of non-adherence to treatment.
One-third of the MLWH had a HADS score of ≥15
(HADS+), indicating psychological distress. This percen-
tage is in line with studies in non-migrant PLWH
Table 1. Socio-demographic characteristics and psychosocial variables.
All
N=306
HADS ≥15
N = 106
HADS < 15
N = 200 P
Age (mean, sd) 41.7 (10.5) 40.9 (10.5) 42.2 (10.6) 0.30a
Male gender (%) 175 (57.2) 54 (50.9) 121 (60.5) 0.11b
1st generation immigrant (%) 288 (94.1) 99 (93.4) 189 (94.5) 0.69b
Region of origin (%) 0.71b
Sub-Saharan Africa 117 (38.2) 44 (41.5) 73 (36.5)
Caribbean 61 (19.9) 18 (17.0) 43 (21.5)
Latin America 72 (23.5) 26 (24.5) 46 (23.0)
Other 56 (18.3) 18 (17.0) 38 (19.0)
Receiving cART (%)# 0.22c
>6 months 259 (84.6) 87 (82.1) 172 (86.0)
<6 months 22 (7.2) 11 (10.4) 11 (5.5)
No cART 22 (7.2) 6 (5.7) 16 (8.0)
CD4 cell count (%) 0.47c
<200 cells/mm3 19 (6.2) 8 (7.5) 11 (5.5)
200–349 cells/mm3 34 (11.1) 9 (8.5) 25 (12.5)
≥350 cells/mm3 253 (82.7) 89 (84.0) 164 (82.0)
HIV-RNA >50 copies/ml (%)* 27 (10.4) 11 (12.6) 16 (9.3) 0.41b
Sexual orientation (%)e 0.54c
Heterosexual 186 (60.8) 68 (64.2) 118 (59.0)
Homosexual/Bisexual 110 (35.9) 34 (32.1) 76 (38.0)
Does not know 7 (2.3) 3 (2.8) 4 (2.0)
Living situation (%) 0.62b
With family 127 (41.5) 45 (42.5) 82 (41.0)
Alone 110 (35.9) 34 (32.1) 76 (38.0)
Single parent 48 (15.7) 20 (18.9) 28 (14.0)
Other 21 (6.9) 7 (6.6) 14 (7.0)
Children (%) 172 (56.2) 60 (56.6) 112 (44.0) 0.92b
Educational attainment (%)e 0.57b
No formal education / Primary school 63 (20.6) 26 (24.5) 37 (18.5)
Secondary school 96 (31.4) 33 (31.1) 63 (31.5)
Higher vocational school 77 (25.2) 23 (21.7) 54 (27.0)
University 68 (22.2) 23 (21.7) 45 (22.5)
Employment status (%) <0.001b
Paid employment 133 (43.5) 31 (29.2) 102 (51.0)
Unemployed 79 (25.8) 33 (31.1) 46 (23.0)
On sick leave 33 (10.8) 23 (17.9) 10 (5.0)
Other 61 (19.9) 19 (17.9) 42 (21.0)
Alcohol (%)
Alcohol in the past 30 days 178 (58.2) 62 (58.8) 116 (58.0) 0.93b
Alcohol use ≥3 days/week 51 (16.7) 19 (17.9) 32 (16.0) 0.67b
Drugs (%)
Drugs in the past 3 days 53 (17.3) 21 (19.8) 32 (16.0) 0.40b
Drugs use ≥3 days/week 30 (9.8) 12 (11.3) 18 (9.0) 0.52b
Psychosocial variables (median, IQR)e
Social support 32 (22–37) 62.5 (31.3–84.4) 79.7 (50.0–93.8) <0.001d
Internalized HIV-related stigma 15 (12–18.3) 17 (13.8–21.0) 14 (12–17) <0.001d
Adherence self-eﬃcacy 104 (89.3–115) 99 (80–111) 109 (95–117) <0.001d
Quality of life (physical) 52.4 (42.6–56.4) 46.0 (35-1–54.6) 53.8 (46.8–56.6) <0.001d
Quality of life (mental) 48.9 (37.6–56.6) 35.9 (30.1–45.2) 53.6 (44.2–58.7) <0.001d
Self-reported adherence (%)*
Adherence <0.001b
Adherent 121 (46.7) 25 (28.7) 96 (55.8)
Non-adherent 137 (52.9) 62 (71.3) 75 (43.6)
IQR, interquartile range; cART, combination antiretroviral therapy; Int., internalized.
#Participants who were previously treated with cART due to an acute HIV-infection (n = 3) were excluded from this analyses.
*Participants who were >6 months on cART (N = 259). In HADS = <15 group, 1 participant had a missing value for self-reported adherence.
aT-test.
bChi-square.
cFisher-Freeman-Halton Exact.
dMann-Whitney Test.
eMissing values: sexual orientation (N = 3), educational attainment (N = 2), social support (N = 16), internalized HIV related stigma (N = 12), treatment adherence
self-eﬃcacy (N = 50), physical quality of life (N = 4), and mental quality of life (N = 4).
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(Ibbotson et al., 1994; Kugaya et al., 2000). In addition,
participants with a HADS+ less often received paid
employment and were on sick leave more often com-
pared to participants with a HADS−. A recent study
showed that entering paid employment for ≥12 hours
per week resulted in better mental health in people
with mental health problems (Schuring, Robroek, & Bur-
dorf, 2017). These results indicate that supporting
patients with mental health problems in starting (part
time) jobs with paid employment might improve their
mental health status. However, it is possible that partici-
pants experienced psychological distress due to losing
paid employment or being unable to work due to
psychological distress. Future research should take the
reasons for unemployment into account to determine
appropriate interventions. Furthermore, worse results
on psychosocial outcomes (like higher internalized
HIV-related stigma, less experienced social support,
less treatment adherence self-eﬃcacy, and lower quality
of life) were found in participants with a HADS+ com-
pared to participants with a HADS−. These results are
in line with previous studies on the association between
symptoms of psychological distress and various psycho-
social outcomes in patients with chronical illness (Betan-
cur, Lins, Oliveira, & Brites, 2017; Eller et al., 2014;
Rendina, Millar, & Parsons, 2018; Wu et al., 2013). In
line with a meta-analysis (Uthman et al., 2014), our
data indicate that participants with a HADS+ were
more likely to be non-adherent to cART.
The HADS showed good internal consistency with a
Cronbach’s α of 0.87 for the HADS-T, 0.79 for the
HADS-A, and 0.76 for the HADS-D. The results from
the subscales are slightly lower than the α’s in a study
where 747 papers were reviewed (Bjelland et al., 2002).
Mean α’s of 0.83 for the HADS-A 0.83 and 0.82 for the
HADS-D were reported. The α of the HADS-T is in
line with the α reported in a validation study of the
HADS in diﬀerent Dutch populations, which ranged
from 0.82 to 0.90 (Spinhoven et al., 1997). In addition,
in 21/37 (57%) a diagnosis of depression or anxiety dis-
order based on the CIDI and 4/23 (17%) of the partici-
pants with a HADS− were diagnosed with a depressive
or anxiety disorder based on the CIDI as well (P <
0.01). However, the HADS seemed to be only a snapshot
of the participants’ symptoms of psychological distress
since the score changed from a HADS+ to a HADS−
in 39% of the participants that were retested after
a more than 3 month time period. Previous studies
have shown variable test-retest reliability scores ranging
from 0.91 for the HADS-T with a maximum of three
weeks between administrations, 0.46 and 0.43 for the
HADS-A and HADS-D with a maximum of 90 days
between administrations (McPherson & Martin, 2011;
Spinhoven et al., 1997). However, lower scores have
been found with less time between the tests as well
(McPherson & Martin, 2011). Therefore, results from
the HADS should not be seen as a given for a longer
period of time. It should be repeated, even after several
weeks have passed.
A strength of our study was that the HADS was
completed by 87% (306/352) in a multicultural, multi-
lingual population. Therefore, it has shown that the use
of this screening tool in a diﬃcult to reach and diag-
nose population is possible based on the use of trans-
lated versions of the HADS. However, as the language
may not be a large problem in cross cultural study
populations, the interpretation of the resulted may
be. Maters, Sanderman, Kim, and Coyne (2013)
reported that very few validation studies report about
challenges in cross-cultural use of the HADS (Maters
et al., 2013). Additionally, several interviewers reported
participants having diﬃculties in interpreting some of
the questions, e.g., the interpretation of the phrase
“butterﬂies in the stomach”. Therefore, validations
studies of translations of the HADS should always
take the cultural background of its participants into
consideration. Lastly, we found that a large proportion
of the participants (78%) completed the HADS in
Dutch. This might be explained by the fact that
about 30% of the participants originate from former
Dutch colonies in the Caribbean and Surinam where
Dutch is (one of the) main language(s). In addition,
Table 2. Summary statistics of the HADS-A, HADS-D, and HADS-T.
Median (IQR)
Subscale score
8–10 (%)
Subscale score
≥11 (%)
Cronbach’s
α
HADS-A 6.0 (3.0–10.0) 46 (15.0) 71 (23.2) 0.79
HADS-D 5.0 (2.0–8.0) 46 (15.0) 39 (12.7) 0.76
HADS-T 11.0 (6.0–17.0) 0.87
A, anxiety; D, depression; T, total.
Table 3. Association between HADS and CIDI.
HADS+a HADS−a Total
CIDI+ 21 4 25
CIDI- 16b 19 35
Total 37 23 60c
HADS+, HADS score ≥; HADS−, HADS score <15; CIDI+, diagnosis on
depression or anxiety; CIDI-, no diagnosis on depression or anxiety.
aIn this analyses the HADS results are those from the HADS that was com-
pleted just before the CIDI. In 58 participants, these are the results from
the second assessment. All these participants had a HADS+ in the ﬁrst
assessment.
bIn four participants with a HADS+ the results from the CIDI showed minor
symptoms or an anxiety or depressive disorder, but no oﬃcial diagnosis.
They were categorized in the CIDI- group.
cFive participants partially completed the CIDI due to a language barrier, lack
of time, and emotional reaction to the questions. One was excluded from
analyses as no section was completed. Four were included as they com-
pleted the anxiety section.
984 S. BEEN ET AL.
about 90% of the participants have lived in the Nether-
lands for ≥5 years at the time of inclusion.
A possible limitation of our study is that although 106
participants were eligible to complete the CIDI, the
administration of the CIDI proved to be challenging in
this population. The CIDI was initiated in 61 (57.5%)
and completed by 60. In this study, it was possible to
administer the CIDI in Dutch and English. Licenses for
translations in French and Spanish were not available,
which excluded several participants from the CIDI. In
addition, a large proportion of the participants that did
not initiate the CIDI 32/39 (82%) refused to participate,
could not be reached to make an appointment, or did not
show up at their appointment. Furthermore, when the
CIDI was started, the time spend to complete the CIDI
varied between 15 minutes to several hours and language
barriers were common reasons for the delay in com-
pletion. Another limitation is that the properties of the
CIDI as a diagnostic test were based on the results of
the participants with an initial a HADS+. The ideal pro-
cedure would have been to have oﬀered the CIDI to par-
ticipants with an initial HADS− as well. However, we
believe that this would not have been feasible because
of the expected additional burden (time investment)
for the 200 participants. A ﬁnal limitation might be
that by using the HADS-T to determine symptoms of
psychological distress, some participants who had a
higher score on only one of the two subscales may
have been “missed”. Previous studies have used cut-oﬀ
scores of ≥8 or ≥11 for the individual subscales (Bjelland
et al., 2002). In our study, 33 participants had a HADS-A
or HADS-D score of ≥8 and did not have a HADS-T of
≥15 and four participants had a HADS-A or HADS-D
score of ≥11 and did not have a HADS-T of ≥15.
In conclusion, in a large group of MLWH in the Neth-
erlands, more than 34% were at risk for psychological
distress (HADS+). In 57% of the participants, a HADS
+ indicated a diagnosis of depression or anxiety disorder
based on the CIDI. However, the HADS score seems to
be only a snapshot of symptoms of psychological distress
and should be repeated after several weeks. In MLWH,
screening for symptoms of anxiety and depression
should be part of their treatment given the association
with self-reported non-adherence. The HADS seems to
be suitable for MPLWH from diﬀerent cultural back-
grounds. When administering the HADS and interpret-
ing its results, the cultural background of its participants
should be taken into consideration.
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